EZH1/2双重抑制打破急性髓系白血病白血病干细胞的静息状态
急性髓系白血病(AML)复发由残留的耐药白血病干细胞(LSC)导致。本研究发现静息LSC高表达EZH1和EZH2,小鼠AML模型中Ezh1/2基因缺失可诱导静息LSC进入细胞周期并分化,最终清除LSC;新开发的EZH1/2双重抑制剂在AML小鼠模型和患者来源异种移植模型中减少LSC数量、抑制白血病进展并延长生存。
要点
- 静息LSC在AML层级中表达最高水平的EZH1和EZH2。
- 小鼠AML模型中Ezh1/2基因缺失诱导静息LSC细胞周期进展和分化,最终清除LSC。
- EZH1/2双重抑制剂在AML小鼠模型和患者来源异种移植模型中减少LSC、抑制进展并延长生存。
核心结论
- EZH1/2双重抑制是清除AML LSC的有效策略。
研究设计与样本
- 研究使用小鼠AML模型和患者来源异种移植模型,并开发了新型EZH1/2双重抑制剂。
主要发现
- 静息LSC在AML层级中表达最高水平的EZH1和EZH2。
- 小鼠AML模型中Ezh1/2基因缺失诱导静息LSC细胞周期进展和分化为LSC,最终清除AML LSC。
- 静息LSC显示PRC2介导的Cyclin D抑制,过表达Cyclin D的AML对化疗更敏感。
- EZH1/2双重抑制剂在AML小鼠模型和患者来源异种移植模型中减少LSC数量、损害白血病进展并延长生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is an aggressive and lethal blood cancer originating from rare populations of leukemia stem cells (LSCs). AML relapse after conventional chemotherapy is caused by a remaining population of drug-resistant LSCs. Selective targeting of the chemoresistant population is a promising strategy for preventing and treating AML relapse. Polycomb repressive complex 2 (PRC2) trimethylates histone H3 at lysine 27 to maintain the stemness of LSCs. Here, we show that quiescent LSCs expressed the highest levels of enhancer of zeste (EZH) 1 and EZH2, the PRC2 catalytic subunits, in the AML hierarchy, and that dual inactivation of EZH1/2 eradicated quiescent LSCs to cure AML. Genetic deletion of Ezh1/2 in a mouse AML model induced cell cycle progression of quiescent LSCs and differentiation to LSCs, eventually eradicating AML LSCs. Quiescent LSCs showed PRC2-mediated suppression of Cyclin D, and Cyclin D-overexpressing AML was more sensitive to chemotherapy. We have developed a novel EZH1/2 dual inhibitor with potent inhibitory activity against both EZH1/2. In AML mouse models and patient-derived xenograft models, the inhibitor reduced the number of LSCs, impaired leukemia progression, and prolonged survival. Taken together, these results show that dual inhibition of EZH1/2 is an effective strategy for eliminating AML LSCs.
引用
- Fujita S, Honma D, Adachi N, et al. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. Leukemia. 2017. PMID: 28951561. doi:10.1038/leu.2017.300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。